Published in Am J Pathol on November 01, 1990
NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc Natl Acad Sci U S A (1995) 1.32
Beta protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. Am J Pathol (1992) 1.20
Brain extracellular matrix in neurodegeneration. Brain Pathol (2008) 1.15
Polarized secretion of beta-amyloid precursor protein and amyloid beta-peptide in MDCK cells. Proc Natl Acad Sci U S A (1994) 1.12
Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. J Cell Biol (2003) 1.11
Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am J Pathol (1994) 0.99
Butyrylcholinesterase is associated with β-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease. J Neuropathol Exp Neurol (2012) 0.95
Tangle-associated neuritic clusters. A new lesion in Alzheimer's disease and aging suggests that aggregates of dystrophic neurites are not necessarily associated with beta/A4. Am J Pathol (1992) 0.92
Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease. Mol Neurobiol (2007) 0.92
Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. Am J Pathol (1999) 0.91
The tauopathies: toward an experimental animal model. Am J Pathol (1999) 0.91
Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains. Acta Neuropathol (1993) 0.91
Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am J Pathol (1994) 0.87
Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques. Acta Neuropathol (1995) 0.87
Inhibitors of myelination: ECM changes, CSPGs and PTPs. Exp Neurol (2013) 0.86
Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol Neurodegener (2007) 0.86
Suppression of amyloid beta A11 antibody immunoreactivity by vitamin C: possible role of heparan sulfate oligosaccharides derived from glypican-1 by ascorbate-induced, nitric oxide (NO)-catalyzed degradation. J Biol Chem (2011) 0.85
Cellular Interaction and Cytotoxicity of the Iowa Mutation of Apolipoprotein A-I (ApoA-IIowa) Amyloid Mediated by Sulfate Moieties of Heparan Sulfate. J Biol Chem (2015) 0.82
Expression and distribution of amyloid precursor protein-like protein-2 in Alzheimer's disease and in normal brain. Am J Pathol (1996) 0.81
Sulfatides facilitate apolipoprotein E-mediated amyloid-beta peptide clearance through an endocytotic pathway. J Neurochem (2008) 0.81
A role for extracellular matrix degradation and matrix metalloproteinases in senile dementia? Acta Neuropathol (1994) 0.81
Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimer's Disease. PLoS One (2015) 0.80
The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease. Mol Neurobiol (2010) 0.80
Progressive supranuclear palsy. Mol Pathol (2001) 0.80
Cholinesterases colocalize with sites of neurofibrillary degeneration in aged and Alzheimer's brains. Acta Neuropathol (1994) 0.80
Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques? Am J Pathol (1997) 0.80
Sulfated glycosaminoglycans in protein aggregation diseases. Glycoconj J (2017) 0.77
Heparan sulfate proteoglycans mediate Aβ-induced oxidative stress and hypercontractility in cultured vascular smooth muscle cells. Mol Neurodegener (2016) 0.75
Heparan sulfate proteoglycan induces the production of NO and TNF-alpha by murine microglia. Immun Ageing (2005) 0.75
Extracellular matrix proteomics in schizophrenia and Alzheimer's disease. Anal Bioanal Chem (2016) 0.75
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 20.07
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A (1986) 6.56
Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J (1985) 6.24
Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science (1987) 5.06
Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest (1987) 4.98
Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau) Proc Natl Acad Sci U S A (1986) 4.26
The fine structure of some intraganglionic alterations. Neurofibrillary tangles, granulovacuolar bodies and "rod-like" structures as seen in Guam amyotrophic lateral sclerosis and parkinsonism-dementia complex. J Neuropathol Exp Neurol (1968) 4.14
Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc Natl Acad Sci U S A (1985) 3.54
Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell (1988) 3.11
Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A (1987) 2.97
Aberrant neurofilament phosphorylation in Alzheimer disease. Proc Natl Acad Sci U S A (1985) 2.96
Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. Proc Natl Acad Sci U S A (1985) 2.86
Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol (1988) 2.84
Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell (1980) 2.76
Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature (1989) 2.17
The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II. Nature (1989) 1.94
Spectrum of morphological appearance of amyloid deposits in Alzheimer's disease. Acta Neuropathol (1989) 1.93
Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging (1988) 1.89
Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol (1988) 1.81
Protease nexin. Properties and a modified purification procedure. J Biol Chem (1985) 1.66
The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Pathol (1988) 1.65
A prospective study of Alzheimer disease in Down syndrome. Arch Neurol (1989) 1.64
A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol (1989) 1.62
The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev (1988) 1.56
The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol (1984) 1.49
Amyloid beta protein precursor is possibly a heparan sulfate proteoglycan core protein. Science (1988) 1.46
Altered structural proteins in plaques and tangles: what do they tell us about the biology of Alzheimer's disease? Neurobiol Aging (1987) 1.42
Antisera to an amino-terminal peptide detect the amyloid protein precursor of Alzheimer's disease and recognize senile plaques. Biochem Biophys Res Commun (1988) 1.41
Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci U S A (1989) 1.40
Physicochemical characteristics of the glycosaminoglycan-lysosomal enzyme interaction in vitro. A model of control of leucocytic lysosomal activity. Biochem J (1976) 1.33
Induction of secretion of IgM from cells of the B cell line 38c-13 by somatic cell hybridization. J Immunol (1979) 1.32
Alzheimer neurofibrillary tangles contain phosphorylated and hidden neurofilament epitopes. J Neurol Neurosurg Psychiatry (1986) 1.27
Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer's disease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system. Am J Pathol (1989) 1.24
Diffuse lipofuscinosis of the central nervous system. Neurology (1967) 1.23
Lipoprotein pigments--their relationship to ageing in the human nervous system. I. The lipofuscin content of nerve cells. Brain (1974) 1.19
Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging (1989) 1.19
Alzheimer's disease and Down's syndrome. Histopathology (1988) 1.18
Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro. Biochem J (1975) 1.15
Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J (1988) 1.13
The structure and metabolism of mucopolysaccharides (glycosaminoglycans) and the problem of the mucopolysaccharidoses. Am J Med (1969) 1.12
Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer's disease and their relationship to ageing and to the accumulation of lipofuscin pigment. Mech Ageing Dev (1984) 1.11
Basement membrane proteoglycan in various tissues: characterization using monoclonal antibodies to the Engelbreth-Holm-Swarm mouse tumor low density heparan sulfate proteoglycan. J Cell Biol (1988) 1.11
Sulfated glycosaminoglycans in Alzheimer's disease. Hum Pathol (1987) 1.09
Immunoreactivity of neuronal lipofuscin with monoclonal antibodies to the amyloid beta-protein. Neurobiol Aging (1989) 1.04
An analysis of the morphology of senile plaques in Down's syndrome patients of different ages using immunocytochemical and lectin histochemical techniques. Neuropathol Appl Neurobiol (1989) 0.99
cDNA sequence coding for a rat glia-derived nexin and its homology to members of the serpin superfamily. Biochemistry (1987) 0.96
Neuronal lipofuscin accumulation in ageing and alzheimer dementia: a pathogenic mechanism? Br J Psychiatry (1982) 0.94
Lipofuscin and lipofuscin-like substances. Chem Phys Lipids (1987) 0.93
Lipofuscin pigment accumulation in human brain during aging. Exp Gerontol (1982) 0.88
The Hurler and Hunter syndromes. Am J Med (1969) 0.88
Glycosaminoglycans on fibroblasts accelerate thrombin inhibition by protease nexin-1. Biochem J (1987) 0.87
Correlative light and electron microscopic immunocytochemistry on the same section with colloidal gold. J Histochem Cytochem (1987) 0.87
Arterial chondroitin sulfate proteoglycan: localization with a monoclonal antibody. J Histochem Cytochem (1988) 0.86
Studies on chemical nature of lipofusion (age pigment) isolated from normal human brain. Lipids (1975) 0.86
Cationic dyes reveal proteoglycans structurally integrated within the characteristic lesions of Alzheimer's disease. Acta Neuropathol (1989) 0.85
A quantitative study of lipofuscin accumulation with age in normals and individuals with Down's syndrome, phenylketonuria, progeria and transneuronal atrophy. J Comp Neurol (1979) 0.85
Protease nexin I immunostaining in Alzheimer's disease. Ann Neurol (1989) 0.85
Immunohistochemical study of Alzheimer's disease using antibodies to synthetic amyloid and fibronectin. J Neurol Sci (1988) 0.84
Effect of heparin on the glia-derived-nexin-thrombin interaction. Biochem J (1989) 0.84
Colloidal gold immunostaining on deplasticized ultra-thin sections. J Histochem Cytochem (1988) 0.81
The pathogenesis and progression of the pathological changes of Alzheimer's disease. Ann Med (1989) 0.78
Redistribution of lipofuscin in aged neurons induced by colchicine. Mech Ageing Dev (1988) 0.77
Relationship between pigment accumulation and age in Alzheimer's disease and Down syndrome. Acta Neuropathol (1984) 0.76
Endoscopic papillary balloon dilation for the management of common bile duct stones: experience of 226 cases. Endoscopy (1998) 4.11
Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem (1999) 3.34
Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc (1999) 2.63
Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (1999) 2.59
Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem (2001) 2.40
Human atherosclerosis. I. Cell constitution and characteristics of advanced lesions of the superficial femoral artery. Am J Pathol (1984) 2.29
Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A (1999) 2.26
The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet (2000) 2.24
Characterization of fibronectin interactions with glycosaminoglycans and identification of active proteolytic fragments. J Biol Chem (1980) 2.24
Light microscopic immunolocation of thrombospondin in human tissues. J Histochem Cytochem (1985) 2.20
Mechanism responsible for glucose-lactose diauxie in Escherichia coli: challenge to the cAMP model. Genes Cells (1996) 2.15
Anomalous criticality in the electrical resistivity of La2-xSrxCuO4. Science (2008) 2.15
Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology (1997) 2.13
The influence of p-nitrophenyl beta-d-xyloside on the synthesis of proteochondroitin sulfate by slices of embryonic chick cartilage. J Biochem (1973) 2.08
A chondrogenic cell line derived from a differentiating culture of AT805 teratocarcinoma cells. Cell Differ Dev (1990) 2.00
Mouse cartilage matrix deficiency (cmd) caused by a 7 bp deletion in the aggrecan gene. Nat Genet (1994) 1.94
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Proteoglycans in primate arteries. I. Ultrastructural localization and distribution in the intima. J Cell Biol (1975) 1.93
Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A (1996) 1.92
Structural analysis of chick-embryo cartilage proteoglycan by selective degradation with chondroitin lyases (chondroitinases) and endo-beta-D-galactosidase (keratanase). Biochem J (1980) 1.86
Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol (2001) 1.84
Phenotypic variability of Gerstmann-Sträussler-Scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol (1998) 1.79
An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron (1994) 1.77
Phenotype of chromosome 14-linked familial Alzheimer's disease in a large kindred. Ann Neurol (1994) 1.73
A novel regulatory role of glucose transporter of Escherichia coli: membrane sequestration of a global repressor Mlc. EMBO J (2000) 1.72
Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology (2000) 1.71
The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Pathol (1988) 1.65
A large chondroitin sulfate proteoglycan (PG-M) synthesized before chondrogenesis in the limb bud of chick embryo. J Biol Chem (1986) 1.62
Proteoglycans in primate arteries. II. Synthesis and secretion of glycosaminoglycans by arterial smooth muscle cells in culture. J Cell Biol (1975) 1.60
Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem (1991) 1.55
Isolation of two forms of basement membrane proteoglycans. J Biol Chem (1985) 1.55
Sulfated proteoglycans synthesized by vascular endothelial cells in culture. J Biol Chem (1983) 1.55
Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut (2005) 1.54
Neuronal nuclear antigen (NeuN): a marker of neuronal maturation in early human fetal nervous system. Brain Dev (1998) 1.53
Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function. J Biochem (1998) 1.53
Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation (1998) 1.52
Absence of linkage of chromosome 21q21 markers to familial Alzheimer's disease. Science (1988) 1.44
Defect in SHAP-hyaluronan complex causes severe female infertility. A study by inactivation of the bikunin gene in mice. J Biol Chem (2001) 1.42
Dwarfism and age-associated spinal degeneration of heterozygote cmd mice defective in aggrecan. Proc Natl Acad Sci U S A (1997) 1.42
Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Cancer Res (1999) 1.41
Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and RHAMM. J Clin Invest (1995) 1.41
Biochemical and ultrastructural studies of proteoheparan sulfates synthesized by PYS-2, a basement membrane-producing cell line. J Cell Biol (1982) 1.41
Chondroitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin. J Biol Chem (1986) 1.41
Absence of proteoglycan core protein in cartilage from the cmd/cmd (cartilage matrix deficiency) mouse. J Biol Chem (1981) 1.37
Evidence for the covalent binding of SHAP, heavy chains of inter-alpha-trypsin inhibitor, to hyaluronan. J Biol Chem (1995) 1.37
Isolation and characterization of a third proteoglycan (PG-Lt) from chick embryo cartilage which contains disulfide-bonded collagenous polypeptide. J Biol Chem (1983) 1.37
Enzyme interactions in heparan sulfate biosynthesis: uronosyl 5-epimerase and 2-O-sulfotransferase interact in vivo. Proc Natl Acad Sci U S A (2001) 1.36
Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J Neurochem (1997) 1.34
Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest (1998) 1.32
Molecular characterization of type-specific capsular polysaccharide biosynthesis genes of Streptococcus agalactiae type Ia. J Bacteriol (1999) 1.32
Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases. Neurobiol Aging (2001) 1.32
Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). Ann Neurol (1996) 1.32
Smooth muscle cell expression of extracellular matrix genes after arterial injury. Am J Pathol (1994) 1.32
Immunolocalization of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. Lab Invest (1990) 1.32
A serum-derived hyaluronan-associated protein (SHAP) is the heavy chain of the inter alpha-trypsin inhibitor. J Biol Chem (1993) 1.32
Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries. Circulation (1996) 1.32
Proteoglycans synthesized by smooth muscle cells derived from monkey (Macaca nemestrina) aorta. J Biol Chem (1983) 1.31
Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular smooth muscle cells. J Biol Chem (2001) 1.29
2B1 antigen characteristically expressed on extracellular matrices of human malignant tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Cancer Res (1996) 1.28
In vitro synthesis of hyaluronan by a single protein derived from mouse HAS1 gene and characterization of amino acid residues essential for the activity. J Biol Chem (2000) 1.28
cDNA cloning of PG-M, a large chondroitin sulfate proteoglycan expressed during chondrogenesis in chick limb buds. Alternative spliced multiforms of PG-M and their relationships to versican. J Biol Chem (1993) 1.27
The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem (1999) 1.25
Heterogeneity of proteochondroitin sulfates produced by chondrocytes at different stages of cytodifferentiation. J Biol Chem (1974) 1.25
Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology (2001) 1.25
Organized type I collagen influences endothelial patterns during "spontaneous angiogenesis in vitro": planar cultures as models of vascular development. In Vitro Cell Dev Biol Anim (1995) 1.25
The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine. J Biol Chem (2000) 1.25
Multiple forms of mouse PG-M, a large chondroitin sulfate proteoglycan generated by alternative splicing. J Biol Chem (1995) 1.24
Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care (2001) 1.24
Increased synthesis of hyaluronic acid by mouse mammary carcinoma cell variants with high metastatic potential. Cancer Res (1983) 1.22
Substrate specificity of the heparan sulfate hexuronic acid 2-O-sulfotransferase. Biochemistry (2001) 1.22
A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L) Brain (1999) 1.22
Intracellular localization of hyaluronan in proliferating cells. J Histochem Cytochem (1999) 1.22
Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation (1989) 1.21
Structure of a heparan sulphate oligosaccharide that binds to basic fibroblast growth factor. Biochem J (1992) 1.20
Platelet-derived growth factor stimulates the formation of versican-hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells. Arch Biochem Biophys (2001) 1.20
Avian neural crest cell migration is diversely regulated by the two major hyaluronan-binding proteoglycans PG-M/versican and aggrecan. Development (2000) 1.19
Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging (1989) 1.19
Molecular cloning and expression of Chinese hamster ovary cell heparan-sulfate 2-sulfotransferase. J Biol Chem (1997) 1.19
Familial presenile dementia with psychosis associated with cortical neurofibrillary tangles and degeneration of the amygdala. Neurology (1992) 1.18
Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler Thromb (1993) 1.18
Negative regulation of the pts operon by Mlc: mechanism underlying glucose induction in Escherichia coli. Genes Cells (1999) 1.17
Phenotypic heterogeneity in familial Alzheimer's disease: a study of 24 kindreds. Ann Neurol (1989) 1.17
Regulation of cell-substrate adhesion by proteoglycans immobilized on extracellular substrates. J Biol Chem (1989) 1.17
Expression cloning and molecular characterization of HAS protein, a eukaryotic hyaluronan synthase. J Biol Chem (1996) 1.17
Differential expression of small chondroitin/dermatan sulfate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem (1991) 1.17
Effect of beta-D-xyloside and cycloheximide on the synthesis of two types of proteochondroitin sulfate in chick embryo cartilage. J Biol Chem (1978) 1.16
Distribution of mannosamine and mannosaminuronic acid among cell walls of Bacillus species. J Bacteriol (1982) 1.16
Purification and characterization of heparan sulfate 2-sulfotransferase from cultured Chinese hamster ovary cells. J Biol Chem (1996) 1.15
The occurrence of low buoyant density proteoglycans in embryonic chick cartilage. Biochem Biophys Res Commun (1978) 1.15